RSV infection burden study in SEHA hospitals
Part of Immune system & allergy, Infections, Lungs & breathing clinical trials.
This study looks at how respiratory syncytial virus (RSV) affects people of all ages. It aims to better understand the burden of RSV infections by reviewing medical records of patients treated at SEHA hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed RSV infection (proven by lab test).
- You were admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024.
- Your medical records are available in the SEHA electronic medical record system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at children under 5 who have RSV (a common respiratory virus) and visit a pediatric emergency department in Türkiye. It aims to learn more about how RSV affects young children so doctors can better care for them.
This study looks for markers in the blood that can tell how serious an RSV infection might become. If you are hospitalized with RSV and have breathing symptoms, this trial will follow your recovery and test for clues about your illness.
This study looks at how RSV (a common virus that can affect breathing) leads to illness in young children who come to the doctor with ear infections and/or breathing symptoms. It may help doctors better understand the “burden” RSV causes in both home/outpatient and hospital settings.
This study will safely expose healthy older adults (65-75) to a mild RSV B virus to see how their immune system responds. It may help develop better vaccines or treatments for RSV in older people.
This study tracks how respiratory syncytial virus (RSV)—a common respiratory infection in babies—affects children under 24 months in Ho Chi Minh City. Researchers want to understand how often RSV happens, how severe it is, and how it impacts families, so they can better prepare healthcare services.
This study tests an RSV vaccine in adults aged 18 and older, especially those with chronic health issues like heart or lung disease. It aims to see how safe and effective the vaccine is at preventing RSV infections.
Hear when a new Bronchiolitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.